MANKIND — Mankind Pharma Income Statement
0.000.00%
HealthcareLarge Cap
- IN₹942.70bn
- IN₹913.03bn
- IN₹103.35bn
Annual income statement for Mankind Pharma, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | C2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 58,652 | 62,144 | 77,816 | 87,494 | 103,348 |
Cost of Revenue | |||||
Gross Profit | 38,619 | 43,069 | 52,084 | 56,781 | 69,369 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 45,185 | 46,823 | 59,296 | 71,747 | 81,957 |
Operating Profit | 13,468 | 15,322 | 18,520 | 15,747 | 21,391 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 14,377 | 16,916 | 19,746 | 16,712 | 23,994 |
Provision for Income Taxes | |||||
Net Income After Taxes | 10,561 | 12,930 | 14,530 | 13,097 | 19,418 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 10,304 | 12,654 | 14,335 | 12,819 | 19,129 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 10,304 | 12,654 | 14,335 | 12,819 | 19,129 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 27.3 | 32 | 35.4 | 32.1 | 47.7 |